Reports for APOTEX INC
Company Name
APOTEX INC
Totals |
||
Shortage reports |
3356 |
|
Actual shortage: | 218 (6%) | |
Anticipated shortage: | 0 (0%) | |
Avoided shortage: | 10 (0%) | |
Resolved: | 3128 (93%) | |
Discontinuation Reports |
359 |
|
To be discontinued: | 24 (7%) | |
Discontinued: | 335 (93%) | |
Reversed: | 0 (0%) | |
Late reports |
144 (4%) |
|
Overdue reports |
61 (25%) |
Shortage reports
Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
---|---|---|---|---|---|---|
APO-DASATINIB | 70MG | TABLET | Resolved | 2022-07-19 | 2022-08-12 | 164882 |
APO-DASATINIB | 50MG | TABLET | Resolved | 2022-10-21 | 2022-12-17 | 172360 |
APO-DASATINIB | 100MG | TABLET | Resolved | 2022-11-20 | 2022-12-17 | 175315 |
APO-DASATINIB | 20MG | TABLET | Resolved | 2022-12-05 | 2023-03-16 | 177126 |
APO-DASATINIB | 100MG | TABLET | Resolved | 2020-10-14 | 2020-11-02 | 126277 |
APO-DASATINIB | 50MG | TABLET | Resolved | 2021-01-08 | 2021-03-17 | 131145 |
APO-DASATINIB | 100MG | TABLET | Resolved | 2021-01-29 | 2021-03-25 | 132715 |
APO-DASATINIB | 70MG | TABLET | Resolved | 2021-02-19 | 2021-03-04 | 134430 |
APO-DASATINIB | 70MG | TABLET | Resolved | 2024-04-19 | 2024-06-21 | 225776 |
APO-DEFERASIROX | 500MG | TABLET FOR SUSPENSION | Resolved | 2017-08-24 | 2017-09-22 | 20281 |
APO-DEFERASIROX | 500MG | TABLET FOR SUSPENSION | Resolved | 2018-01-18 | 2018-02-12 | 36432 |
APO-DEFERASIROX | 250MG | TABLET FOR SUSPENSION | Resolved | 2024-09-27 | 2024-12-20 | 238844 |
APO-DEFERASIROX | 250MG | TABLET FOR SUSPENSION | Resolved | 2020-08-06 | 2020-11-28 | 121891 |
APO-DEFERASIROX | 250MG | TABLET FOR SUSPENSION | Resolved | 2020-04-13 | 2020-05-22 | 111901 |
APO-DEFERASIROX | 500MG | TABLET FOR SUSPENSION | Resolved | 2020-05-08 | 2020-05-22 | 114285 |
APO-DEFERASIROX | 500MG | TABLET FOR SUSPENSION | Resolved | 2020-06-04 | 2020-07-28 | 116533 |
APO-DEFERASIROX | 250MG | TABLET FOR SUSPENSION | Resolved | 2018-03-13 | 2018-07-03 | 42717 |
APO-DEFERASIROX | 250MG | TABLET FOR SUSPENSION | Resolved | 2023-09-07 | 2023-09-15 | 203819 |
APO-DEFERASIROX | 250MG | TABLET FOR SUSPENSION | Actual shortage | 2025-04-10 | 2025-05-01 | 254838 |
APO-DEFERASIROX (TYPE J) | 180MG | TABLET | Resolved | 2025-02-13 | 2025-02-21 | 250319 |
Discontinuation reports
Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
---|---|---|---|---|---|---|
APO-LAMIVUDINE | 300MG | TABLET | Discontinued | 2018-09-07 | 2019-07-13 | 60560 |
APO-LAMIVUDINE HBV | 100MG | TABLET | Discontinued | 2018-09-07 | 2019-12-21 | 60563 |
APO-LATANOPROST-TIMOP | Discontinued | 2018-09-07 | 2018-09-15 | 60572 | ||
APO-LEVOCARB | 25MG 250MG | TABLET | Discontinued | 2018-09-07 | 2019-02-07 | 60576 |
APO-LISINOPRIL | 10MG | TABLET | Discontinued | 2018-09-07 | 2019-02-02 | 60579 |
APO-LISINOPRIL | 20MG | TABLET | Discontinued | 2018-09-07 | 2018-11-26 | 60582 |
APO-LISINOPRIL | 5MG | TABLET | Discontinued | 2018-09-07 | 2019-02-13 | 60585 |
APO-LISINOPRIL/HCTZ | 12.5MG 20MG | TABLET | Discontinued | 2017-03-13 | 2017-03-13 | 1090 |
APO-LISINOPRIL/HCTZ | 12.5MG 10MG | TABLET | Discontinued | 2017-03-13 | 2017-03-13 | 1093 |
APO-LISINOPRIL/HCTZ | 25MG 20MG | TABLET | Discontinued | 2017-03-13 | 2017-03-13 | 1096 |
APO-LITHIUM CARBONATE | 300MG | CAPSULE | Discontinued | 2018-09-07 | 2018-09-15 | 60588 |
APO-LOPERAMIDE | 2MG | TABLET | Discontinued | 2017-03-31 | 2017-03-31 | 4930 |
APO-LORAZEPAM | 0.5MG | TABLET | Discontinued | 2018-09-07 | 2018-12-28 | 60591 |
APO-LORAZEPAM | 1MG | TABLET | Discontinued | 2018-09-07 | 2018-10-05 | 60594 |
APO-LOSARTAN | 25MG | TABLET | Discontinued | 2019-02-01 | 2019-02-02 | 74376 |
APO-LOSARTAN | 50MG | TABLET | Discontinued | 2018-09-10 | 2018-09-15 | 60987 |
APO-LOSARTAN | 100MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71213 |
APO-LOSARTAN/HCTZ | 12.5MG 100MG | TABLET | Discontinued | 2018-09-07 | 2018-11-02 | 60597 |
APO-LOSARTAN/HCTZ | 25MG 100MG | TABLET | Discontinued | 2018-09-07 | 2018-12-28 | 60600 |
APO-LOSARTAN/HCTZ | 12.5MG 50MG | TABLET | Discontinued | 2018-09-07 | 2018-12-28 | 60603 |